Previous 10 | Next 10 |
2023-12-26 13:19:25 ET Gainers: RayzeBio ( RYZB ) +101% . IMAC Holdings ( BACK ) +73% . Bit Brother Limited ( BETS ) +63% . Gracell Biotechnological ( GRCL ) +60% . Volcon ( VLCN ) +54% . Sight Sciences ( SGHT ) +45% ...
2023-12-26 12:20:05 ET DENVER, Colo., Dec. 26, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual midday volume; Inspira Technologies Oxy BHN Ltd (NASDAQ: IINN), Gracell Biotechnologies Inc (NASDAQ: GRCL), 60 Degree...
2023-12-26 10:14:39 ET DENVER, Colo., Dec. 26, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual volume; Inspira Technologies Oxy BHN Ltd (NASDAQ: IINN), Brainstorm Cell Therapeutics Inc (NASDAQ: BCLI), 60 Degrees ...
2023-12-26 10:02:19 ET More on Health Care Select Sector SPDR XLV Likely Back To Outperforming XLV: Considering The Low-Maintenance Option To Navigate The Healthcare Sector Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tu...
2023-12-26 08:22:28 ET Gainers: RayzeBio ( RYZB ) +100% on being acquired by Bristol Myers Squibb . Gracell Biotechnologies ( GRCL ) +60% to acquire Gracell, furthering cell therapy ambition across oncology and autoimmune diseases . IMAC Holdings ( BA...
2023-12-26 06:47:11 ET Summary AstraZeneca to acquire China-based Gracell Biotechnologies for up to $1.2 billion. Manchester United sells 25% stake to billionaire Jim Ratcliffe for $1.3 billion. Nano Dimension submits all-cash proposal to buy Stratasys for $16.50 a share. ...
2023-12-26 05:24:51 ET U.S. stock future on Tuesday edged higher on Tuesday to start the holiday-shortened week. The major averages are expected to extend their winning streak until the end of the year, as further signs of cooling US inflation reinforced bets that the Federal R...
2023-12-26 03:42:42 ET More on AstraZeneca, Gracell Biotechnologies: AstraZeneca: A $1.1B Shot In The Arm From Icosavax Acquisition AstraZeneca Pays Hefty Price For Chinese Weight-Loss Drug FDA approves AstraZeneca, Ionis drug for ATTRv-PN Gracell gain...
Includes clinical-stage autologous BCMA/CD19 CAR-T therapy targeting haematologic malignancies and autoimmune diseases, and proprietary cell therapy manufacturing platform AstraZeneca has entered into a definitive agreement to acquire Gracell Biotechnologies Inc. (Gracell, NASDAQ: GRC...
Expands clinical development of GC012F in rSLE following FDA IND clearance for Phase 1/2 trial in the United States Gracell is pioneering use of a CD19/BCMA dual-targeted CAR-T cell therapy in rSLE, aiming for deeper and wider depletion of disease-causing antibody secreting cells and B-ce...
News, Short Squeeze, Breakout and More Instantly...
Gracell Biotechnologies Inc. Company Name:
GRCL Stock Symbol:
NASDAQ Market:
Gracell Biotechnologies Inc. Website:
Volcon Inc. (VLCN) is expected to report for Q4 2023 Tenaga Nasional Bhd ADR (TNABY) is expected to report for quarter end 2023-12-31 Hesai Group (HSAI) is expected to report for Q4 2023 Intrusion Inc. (INTZ) is expected to report $-0.14 for Q4 2023 Eliem Therapeutics Inc (ELYM) i...
SAN DIEGO and SUZHOU, China and SHANGHAI, China, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (“Gracell” or the “Company”, NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing innovative and highly efficacious cell ...
Gracell Biotechnologies Inc. (NASDAQ: GRCL) is the focus of IBN's latest stock spotlight. The company's shares have moved -0.49% on the day to $10.19. Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of ...